Unlock instant, AI-driven research and patent intelligence for your innovation.
Novel drug combination scheme for treating cancers
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A combination, cancer technology, applied in the field of medicine, can solve huge and complex problems, achieve huge application prospects, improve curative effect, and huge development potential.
Inactive Publication Date: 2016-10-12
SUN YAT SEN UNIV CANCER CENT
View PDF4 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Therefore, the research and utilization of new drug combination regimens for old drugs is a huge and complex research topic.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0049] Firstly, the drug sensitivity of six liver cancer cells Hep3B, SMMC-7721, BEL-7402, Huh-7, PLC / PRF / 5, SK-Hep-1 and a liver immortalized cell L02 to Sorafenib was tested.
[0050] 1. Experimental method
[0051] After the cells were plated on a 96-well plate and adhered to the wall overnight, a series of sorafenib concentrations from high to low were prepared, and a control group was set up, added to the wells, and three replicate wells were set for each concentration. After incubating in the cell culture incubator for 48 hours, MTS was added, and after 2 hours, the cell OD value at a wavelength of 490 nm was detected by a multifunctional microplate reader, and the IC50 (half maximal inhibitory concentration) value of sorafenib acting on different cells was calculated.
[0052] 2. The result is as follows figure 1 as shown, figure 1 Among them, graph A is the dose-effect curve after treating each liv...
[0056] Using dozens of tumor-related therapeutic drugs applied from the US NIH / NCI and Sorafenib to screen the combined drug regimen in Hep3B cells.
[0057] 1. Experimental method
[0058] Hep3B liver cancer cells were paved in 96-well plates, and after adhering to the wall overnight, the cells were divided into blank control group, DMSO control group, Sorafenib single drug group, NCI single drug group, and Sorafenib and NCI drug combined drug group, Three replicate wells in each group were added with the corresponding medium or drug solution, and after incubation for 48 hours, the cell proliferation was detected by the MTS method, and the drug interaction coefficient CDI value of different combined drug regimens was calculated according to the cell OD value.
[0059] CDI1 means that the combined drug regimen shows an antagonistic effect.
[0060] 2. The result is as follows figure 2 as shown, figure 2 In the figure A, aft...
Embodiment 3
[0062] Example 3 Study on the Combination of Sorafenib and Fludarabine Phosphate
[0063] 1. In order to verify the above results, the combination of sorafenib and fludarabine phosphate was applied to five liver cancer cells: SMMC-7721, BEL-7402, Huh-7, PLC / PRF / 5, and SK-Hep-1. The method is the same as that for Hep3B in Example 2.
[0064] 2. The result is as follows image 3 as shown, image 3 Among them, picture A is the result verified in SMMC-7721 cells; picture B is the result verified in BEL-7402 cells; picture C is the result verified in Huh-7 cells; picture D is the result verified in PLC / PRF / 5 The results verified in cells; Figure E shows the results verified in SK-Hep-1 cells.
[0065] The combination of sorafenib and fludarabine phosphate showed the most obvious synergistic effect, and four of the five cell types showed synergistic effect (CDI<1).
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a novel drug combination scheme for treating caners (particularly the liver cancer), namely a sorafenib and fludarabine phosphatecombination drug scheme, and particularly comprises application of combination of sorafenib and fludarabine phosphate for preparing medicine for treating cancer and a medicine comprising sorafenib and fludarabine phosphate. A sorafenib and fludarabine phosphate combination drug shows the synergistic interaction, the curative effect of sorafenib for a patient suffering from the liver cancer and the survival benefit obtaining potential of the patient suffering from the liver cancer are improved, and the sorafenib and fludarabine phosphate combination drug treatment scheme can be adopted for a patient who has the limited curative effect or large side effect of sorafenib monotherapy so as to improve the curative effect of sorafenib, improve the life quality and prolong life time of the patient. The drug combination scheme provides the novel treatment thought and solution strategy for clinic treatment for the liver cancer, and the novel drug combination scheme has the huge development potential and application prospect for pushing clinic treatment for the liver cancer.
Description
technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to a new drug combination regimen for the treatment of cancer. Background technique [0002] Cancers are usually composed of rapidly growing cells, and they may have a variety of abnormal chromosomes, often pleomorphic and intermorphic to varying degrees. Since the word "cancer" appeared for the first time in the dictionary of human words, people have been "disgusted by talking about cancer", and getting cancer is tantamount to being sentenced to death. From the initial panic and passive waiting, to the later active treatment, drug treatment, surgical treatment, etc., human beings have begun a long "battle against cancer". For example, liver cancer is an important disease that seriously threatens human life and health. It is the fifth most common tumor and the third leading cause of cancer-related death in the world. According to the 2012 global cancer statistics...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More